Recently, ReSearch Pharmaceuticals Services (RPS) CEO Dan Perlman predicted that twelve of the top twenty big pharma companies in the US will be outsourcing their clinical trial work completely. Perlman expects companies to use one of two proposed models, trials done by one or two companies or bringing CRO expertise in-house. The decision for the companies to make between the two options is base solely on control. To read more about this from outsourcing-pharma along with links to other stories covering the topic, go here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.